We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
ImmunoPET/CT imaging of clear cell renal cell carcinoma with [<sup>18</sup>F]RCCB6: a first-in-human study.
- Authors
Wu, Qianyun; Wu, Yanfei; Zhang, You; Guan, Yihui; Huang, Gang; Xie, Fang; Liu, Jianjun; Zhai, Wei; Wei, Weijun
- Abstract
Purpose: The cluster of differentiation (CD70) is a potential biomarker of clear cell renal cell carcinoma (ccRCC). This study aims to develop CD70-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging tracers and explore the diagnostic value in preclinical studies and the potential value in detecting metastases in ccRCC patients. Methods: Four novel CD70-specific single-domain antibodies (sdAbs) were produced and labelled with 18F by the aluminium fluoride restrained complexing agent (AlF-RESCA) method to develop radiotracers. The visualisation properties of the tracers were evaluated in a subcutaneous ccRCC patient–derived xenograft (PDX) model. In a registered prospective clinical trial (NCT06148220), six patients with pathologically confirmed RCC were included and underwent immunoPET/CT examination exploiting one of the developed tracers (i.e., [18F]RCCB6). Results: We engineered four sdAbs (His-tagged RCCB3 and RCCB6, His-tag-free RB3 and RB6) specifically targeting recombinant human CD70 without cross-reactivity to murine CD70. ImmunoPET/CT imaging with [18F]RCCB3 and [18F]RCCB6 demonstrated a high tumour-to-background ratio in a subcutaneous ccRCC PDX model, with the latter showing better diagnostic potential supported by higher tumour uptake and lower bone accumulation. In comparison, [18F]RB6, developed by sequence optimisation, has significantly lower kidney accumulation than that of [18F]RCCB6. In a pilot translational study, [18F]RCCB6 immunoPET/CT displayed ccRCC metastases in multiple patients and demonstrated improved imaging contrast and diagnostic value than 18F-FDG PET/CT in a patient with ccRCC. Conclusion: The work successfully developed a series of CD70-targeted immunoPET/CT imaging tracers. Of them, [18F]RCCB6 clearly and specifically identified inoculated ccRCCs in preclinical studies. Clinical translation of [18F]RCCB6 suggests potential for identifying recurrence and/or metastasis in ccRCC patients.
- Subjects
RENAL cell carcinoma; COMPUTED tomography; CELL imaging; POSITRON emission tomography; DIAGNOSTIC imaging
- Publication
European Journal of Nuclear Medicine & Molecular Imaging, 2024, Vol 51, Issue 8, p2444
- ISSN
1619-7070
- Publication type
Article
- DOI
10.1007/s00259-024-06672-3